BLIS M18 ACHIEVES US FDA GRAS "NO OBJECTION" STATUS

BLIS M18
™
Achieves US FDA GRAS
“No Objection” Status
Blis Technologies Limited announces that their 2
nd
probiotic strain BLIS M18
™
, has
had the issuance of a US Food and Drug Administration ‘Letter of No Objection’.
This follows the BLIS K12 “Letter of No Objection” in 2016.

The Letter of No Objection, more commonly known as GRAS or ‘Generally
Recognized As Safe’, is another recognition of the robust data supporting Blis
probiotics.
It adds a new level of credibility for BLIS M18
™
and has the potential to open
opportunities with larger consumer food and beverage companies in the US, but also
is recognised as a relevant and credible safety assessment by other countries and
multinational companies.
Through the GRAS program, companies may submit their determination supported
by research and expert review that a specific ingredient is Generally Recognized As
Safe. The Letter of No Objection means that the FDA has reviewed the data and has
no questions regarding the notice submitted.
For further information please contact:
Brian Watson
CEO
027 705 9133









About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation
with evidence-based research and the highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and
gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.